Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
Oral Drug Delivery Systems: Delayed-Release Systems01:11

Oral Drug Delivery Systems: Delayed-Release Systems

Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
Drugs Affecting GI Tract Motility: Other Laxatives01:20

Drugs Affecting GI Tract Motility: Other Laxatives

Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early escalation of oral lipid-lowering therapy to achieve LDL-cholesterol targets in patients after myocardial infarction: study protocol for the prospective, open-label HAnnover ChOlesterol Lowering in Acute Coronary Syndrome trial.

Frontiers in cardiovascular medicine·2026
Same author

Clinical-Pharmacological Drug Information Center of Hannover Medical School: Update From a Tertiary Care University Hospital (2022-2024).

Pharmacology research & perspectives·2026
Same author

Human vs. artificial intelligence: Physicians outperform ChatGPT in real-world pharmacotherapy counselling.

British journal of clinical pharmacology·2025
Same author

[Severe late-onset neutropenia after rituximab administration].

Zeitschrift fur Rheumatologie·2025
Same author

Therapeutic Drug Monitoring of Nirmatrelvir/Ritonavir (Paxlovid) in Patients Treated for COVID-19: Results From a Prospective Multicenter Observational Study.

Therapeutic drug monitoring·2024
Same author

The Implementation of a Pretomanid-Based Treatment Regimen for Multidrug-Resistant Tuberculosis: A Case Series.

Deutsches Arzteblatt international·2023

Related Experiment Video

Updated: Jun 25, 2026

Measuring Lactase Enzymatic Activity in the Teaching Lab
04:41

Measuring Lactase Enzymatic Activity in the Teaching Lab

Published on: August 6, 2018

[Lactose-containing tablets for patients with lactose intolerance?].

Gesine Picksak1, Dirk O Stichtenoth

  • 1Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30623 Hannover. Picksak.Gesine@mh-hannover.de

Medizinische Monatsschrift Fur Pharmazeuten
|February 12, 2009
PubMed
Summary

Most patients with lactose intolerance can tolerate the small amounts of lactose used as an excipient in tablets. Informing patients about lactose content and considering lactase enzyme substitution can manage potential gastrointestinal symptoms.

More Related Videos

Formation of Dispersible Taohong Siwu Tablets
05:44

Formation of Dispersible Taohong Siwu Tablets

Published on: February 3, 2023

Related Experiment Videos

Last Updated: Jun 25, 2026

Measuring Lactase Enzymatic Activity in the Teaching Lab
04:41

Measuring Lactase Enzymatic Activity in the Teaching Lab

Published on: August 6, 2018

Formation of Dispersible Taohong Siwu Tablets
05:44

Formation of Dispersible Taohong Siwu Tablets

Published on: February 3, 2023

Area of Science:

  • Pharmaceutical sciences
  • Gastroenterology
  • Clinical pharmacy

Context:

  • Lactose is a common excipient in tablet formulations due to its favorable properties.
  • Lactose intolerance affects a significant portion of the population, presenting challenges in medication adherence.
  • The nocebo effect, where negative expectations cause adverse symptoms, can be triggered by perceived lactose content.

Purpose:

  • To evaluate the tolerability of lactose excipients in tablet formulations for patients with lactose intolerance.
  • To highlight the importance of patient education regarding lactose content in medications.
  • To explore management strategies for gastrointestinal symptoms in lactose-intolerant patients using lactose-containing medications.

Summary:

  • The majority of patients with lactose intolerance can safely consume medications containing small amounts of lactose as an excipient.
  • Patient awareness of the minimal lactose content in pharmaceutical preparations is crucial to mitigate the nocebo effect.
  • Individualized management may involve lactase enzyme supplementation when lactose-free alternatives are unavailable and symptoms persist.

Impact:

  • Informed patient communication can improve medication adherence and reduce unnecessary avoidance of essential treatments.
  • This understanding supports the continued use of lactose as a cost-effective and functional excipient in the pharmaceutical industry.
  • Provides guidance for healthcare professionals in managing patients with lactose intolerance and gastrointestinal complaints related to medication intake.